NEW YORK — Evotec and Indivumed said on Thursday that they have formed a new drug-discovery and -development alliance focused on non-small cell lung cancer.
Under the deal, the companies will use Evotec's bioinformatics analysis platform and drug discovery technologies with Indivumed's IndivuType database, which integrates patients' clinical information with genomic, transcriptomic, proteomic, and digital histopathology data derived from biospecimens.